Phelan RM, Ostermeier M, Townsend CA. Design and synthesis of a beta-lactamase activated 5-fluorouracil prodrug.
Bioorg Med Chem Lett 2009;
19:1261-3. [PMID:
19167216 PMCID:
PMC2838426 DOI:
10.1016/j.bmcl.2008.12.057]
[Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2008] [Revised: 12/09/2008] [Accepted: 12/11/2008] [Indexed: 10/21/2022]
Abstract
An efficient synthesis of a 5-fluorouracil-cephalosporin prodrug is described for use against colorectal and other cancers in antibody and gene-directed therapies. The compound shows stability in aqueous media until specifically activated by beta-lactamase (betaL). The kinetic parameters of the 5-fluorouracil-cephalosporin conjugate were determined in the presence of Enterobacter cloacae P99 betaL (ECl betaL) revealing a K(m)=95.4 microM and V(max)=3.21 microMol min(-1) mg(-1). The data compare favorably to related systems that have been reported and enable testing of this prodrug against cancer cell lines in vitro and in vivo.
Collapse